Skip to content
Back to announcement

20250904_MDLA_Public Expose_31937621_lamp1.pdf

Other Text extracted MDLA

Source file signed link, expires in 15 minutes

This browser can't display the PDF inline. Open it in a new tab.

Extracted text 17

Page 1
Public Expose


September 2025
Page 2
Company Structure
                      PT Ekon Prima                    Dra. Hetty Soetikno             Masyarakat

                           8,99%                            65,94%                          25,07%




 Distribution & Medical Device




                                      75.00%                                                                     51.00%



Distributor                   Distributor                 Marketing and Sales   Manufacturer         Digital Platform
of pharmaceuticals,           of pharmaceuticals and      of medical devices    of medical devices   to aggregate demand on
medical devices, and          health products                                                        prescription drugs at
health products for both      in Cambodia                                                            marketplace
regular and JKN (BPJS) 2
market in Indonesia
Est. 1980                     Est. 2018                   Est. 1981             Est. 2020            Est. 2022



                                                                                                                              2
Page 3
        Milestone
         With over 44 years of expertise, Medela Potentia has
         transformed into one of Indonesia’s premier integrated
         distribution platforms, delivering a diverse range of                                              2023 - Present
         products nationwide — including our own line of
         manufactured medical devices.                                                              ▪   2023 :          expanded into
                                                                                                        cosmetic, beauty and baby
                                                                                 2018 - 2022            products distribution.

                                                                     ▪   2018 :             was     ▪   2023: Enhanced digital
                                                                         established in Cambodia,       offerings through the
                                                    2011                 marking MP’s first             implementation of
                                                                         international expansion.
                                      ▪   2011 :            was                                     ▪   2023:                 factory
                                          established as a holding                                      was officially inaugurated by
                                                                     ▪   2022 :        was
                                          company.                                                      the Minister of Health of
                         2010                                            established as a
                                                                                                        the Republic of Indonesia.
                                      ▪   2011 :          expanded       pharmacy aggregator
                                          into consumer product          to capture growing
            ▪   2010 :                                                                              ▪   2024 :         officially
                                          distribution.                  e-commerce demand.
                was repositioned as                                                                     became a publicly listed
                a sales & marketing                                                                     company.
                arm for medical                                      ▪   2020 :              was
                devices and                                              established as a medical
                launched its own                                         device manufacturer.
                brand, Stardec.



PRIVATE & CONFIDENTIAL                                                                                                                  3
Page 4
        Driving Growth Through Network Expansion
         Nationwide, Interconnected Distribution Network Supporting the Growth of Indonesia's Healthcare System
         Our Infrastructure1                                           Our Sale’s Channels
                                                                                                                                                                                                                                                          New Branches 2024:
         35 Retail Warehouses                                                 >3,500                             >23,000                                                                                                                                  Pangkal Pinang and Palu
         35 Sales Office (Branch)                                             Clinics                            Pharmacies
         3 Representative Sales Office                                        >50,000                            >2,000
         2 National Distribution Center (NDC)                                 Modern Trade                       Government
         >700 Sales force                                                     >3,000
                                                                                                                 Institutions

         Our Capacity1                                                        Hospitals                          >1,300
                                                                                                                 PBF2 & PAK3
         >75,000 m³ storage capacity                                          >20,0004
         >2,000 m³ cold chain capacity                                        Others                                                                                                  NDC




             Our strong
           commitment to
         highest compliance

           Our Penetration

                                                                                                                                                                                                                                                                Cambodia
                                                                                                                                                                                                                                                                  Our infrastructure1
                                                                                                                             Directly
                                     Hospital 97.1%                                   Pharmacies                                                                                                                                                                         3 Branches
                                                                                                                             covered                                                                                  NDC
                                                                                                                                                                                                                                                 1 National Distribution Center (NDC)
                                                                                                                                                                                                                                                                 2 Retail Warehouses
                                                                                     79,8%                                                                                                                                                                            >40 Sales force
                                                                                                                                                                                                                                                                        Our capacity
                      Total 3,2045 hospitals as of 2024.          Total 30,1996 registered pharmacies as of 2021.                                                                                                                                        1,800 m³ storage capacity

        Notes: 1 As of Aug 2024; 2 Pedagang Besar Farmasi (pharmaceutical wholesaler); 3 Pedagang Alat Kesehatan (medical devices wholesaler); 4 Consist of general trade, veterinaries, optics, laboratories, salon and beauty store and others; 5
        Sourced from Kementrian Kesehatan 2024; 6 Sourced from Kementrian Kesehatan 2021;

PRIVATE & CONFIDENTIAL                                                                                                                                                                                                                                                                  4
Page 5
1H 2025 Summary:
Maintaining Growth with Strong Fundamental


   Maintain Overall
                         Strong Profit Growth
   Revenue Growth                                    Additional of New
                              IDR 200 B
      IDR 7.4 T                                          Partners
                               +15.8%
        +3.7%



    Medical Device
                        Strong Growth with New     Committed to ESG with
  Manufacturing: High
                         Initiatives both in B2B    Impactful Activities &
   Growth with New
                           and B2C Platforms         External Recognition
   Product Launched
Page 6
         Sustainable Margin Trend
         Consolidated Profitability Performance
          In IDR Bio, unless otherwise stated

                Net Sales                                     Gross Profit                                      EBITDA                                  Net Profit

8, 000




7, 000




                                                 1,000                                   10.0%


                                                                                                        3.9%                  3.9%     4.0%   400




6, 000
                                                                                9.6%
                                                                                                                                                                         2.7%
                                                                                                 500                                                                              3.0%
                                                  900                                                                                  3.9%


                                                                                                                                              350




                                                          9.3%                           9.5%



                                                  800                                                                                  3.8%

                                                                                                                                                    2.4%
5, 000




                       Gr                                                                        400
                                                                                                                                              300
                                                                                                                                                                                  2.5%




                     +3.7%                        700



                                                                                         9.0%
                                                                                                                                       3.7%




                                                                                                                                              250
4, 000
                                                                                                                                                                                  2.0%
                                                  600                                                                                  3.6%




            7,153              7,420                                                             300




3, 000
                                                  500


                                                                       Gr                8.5%                                          3.5%   200




                                                                                                                                                                                  1.5%




                                                  400
                                                                     +7.1%                                            Gr               3.4%

                                                                                                                                                               Gr
                                                                                 713
                                                                                                                                              150




2, 000
                                                  300
                                                           666                           8.0%
                                                                                                 200



                                                                                                                    +4.0%              3.3%
                                                                                                                                                             +15.8%               1.0%




                                                                                                         281                   292            100

                                                                                                                                                                          200
                                                  200



                                                                                         7.5%
                                                                                                 100
                                                                                                                                       3.2%          173
1, 000
                                                                                                                                                                                  0.5%


                                                                                                                                               50



                                                  100                                                                                  3.1%




                                                                                                                                               -                                  0.0%
   -                                                                                              -                                    3.0%
                                                    -                                    7.0%




           S1'24               S1'25                      S1'24                 S1'25                   S1'24                S1'25                  S1'24               S1'25
                                                            Gross Profit     %GM to NS                     EBITDA      %EBITDA to NS                   PAT    %Net Profit to NS
                    Consolidated

          Continued Top-line                             Improvement on gross                          Stable EBITDA margin                         Double digit growth on
          Growth                                         profit margin trend                           trend                                        net profit, higher than
                                                         driven by principal and                                                                    net sales growth
                                                         product portfolio


         Source : PT Medela Potentia Tbk and its subsidiaries unaudited Jun’25 financial report
Page 7
Healthy cash balance supported by positive operating cash flow
In IDR Bio, unless otherwise stated

                                      Operating                                  Investing                                 Financing
                                      +161 bIDR                                  -113 bIDR                                 +497 bIDR




                                                                                                                     ( 122 )        ( 20 )      ( 19 )
                                                                                                          658

                292            ( 55 )         ( 61 )
                                                             ( 14 )
                                                                            ( 108 )                                                                      881
                                                                                             (6)
 335

Dec'24         EBITDA     Working Capital   Tax Payment       Other         Capital       Short-term   IPO Proceed   Bank Loan   Rent payment   Others   Jun'25
                                                                        Expenditure-Net   Investment




                  Realized Proceed of Public Offering                       Use of Proceed                                              Remaining
                            Share Issuance                 PT Anugrah Argon PT Deca Metric                                           Proceed of Public
           IPO Proceed                          Net Amount                                                                Total
                                 Cost                           Medica          Medica                                                   Offering
         658,000,000,000 22,037,378,960 635,962,621,040 278,000,000,000 35,000,000,000                               313,000,000,000 322,962,621,040


Source : PT Medela Potentia Tbk and its subsidiaries unaudited Jun’25 financial report
Page 8
  Distribution Project & Initiatives Update
                         National Distribution Center            Medan New Warehouse -                        Supply Chain Optimization
                         Acquisition                             Finalization
                                                                                                              • Objectives: Digitalize Planning to
Projects & Initiatives




                         • Executed May 2025                     • Land acquired: 2023                          Improve Productivity & Accuracy
                         • Land size: 10,000 m2                  • Land size: 9,258m2                         • Features: ANAPLAN with AI
                         • Facilities: 13,000 pallet position    • Facilities: 2000 pallet position
      1H 2025




                                                                                                                Optimizer Planning System
                               • Ambient Room <30°C                    • (2°-8°C, <25°C, <30°C)               • Result: Forecast Accuracy & Out of
                               • Cool Room <25°C                 • Start build: Aug 2025                        Stock improvement
                               • Cold Storage 2°-8°C             • Estimated ready: Q4 2026
                                                                                                              Forecast Accuracy     Out of Stock
                                                                                                            100%                   3%




                                                                                                             1H 2024 1H 2025      1H 2024 1H 2025
     2H Focus




                          1. Medan Warehouse ground breaking and start building              3. Cold Chain Capacity Expansion
                          2. Exploration of Additional National Central Warehouse:           4. New Principals
                             Cikarang
Page 9
                       Distribution Project & Initiatives Update

                           National Distribution           Medan New Warehouse -              Supply Chain Optimization                  New Principals
                           Center Acquisition              Finalization
                                                                                             • Objectives: Digitalize Planning to
  Projects & Initiatives




                                                          • Land acquired: 2023                Improve Productivity & Accuracy
                           • Executed May 2025                                                                                               New Principals
                                                                                             • Features: ANAPLAN with AI
                           • Land size: 10,000 m2         • Land size: 9,258m2                                                       3       joined in 1H
        1H 2025




                                                          • Facilities: 2000 pallet            Optimizer Planning System
                           • Facilities: 13,000 pallet
                                                                • (2°-8°C, <25°C, <30°C)     • Result: Forecast Accuracy & Out
                                 • Ambient Room <30°C
                                                          • Start build: Aug 2025              of Stock improvement
                                 • Cool Room <25°C
                                 • Cold Storage 2°-8°C    • Estimated ready: Q4 2026                              Out of Stock
                                                                                              Forecast Accuracy                          1             2
                                                                                               100%                3%
                                                                                                                                    Consumer        Medical
                                                                                                                                     Health         Device

                                                                                              1H 2024 1H 2025     1H 2024 1H 2025
         2H Focus




                                  1. Medan Warehouse ground breaking and start building               3. Cold Chain Capacity Expansion
                                  2. Exploration of Additional National Central Warehouse:            4. New Principals
                                     Cikarang




PRIVATE & CONFIDENTIAL
Page 10
        Expand Margin through Diversification into Medical Devices
      Business Model                                     Manufacturing Facility


                              Own
                             Product



                    Agency
                                                          • Inauguration: December
                                                            21st, 2023
                                 Distribution             • Location: Jababeka II
                                                          • Land area: 5,985 sqm         • Storage area: 1,295 sqm (~1500 pallet)
                                                          • Building area: 4,800 sqm     • ISO 13485 : Wound care and surgical
                                                          • Production area: 3,600 sqm    supplies

                                                         ✔Strengthen own product business
        • Provide end to end solution for customer and   ✔Government implemented a national health transformation to increase
          business partners                               resilience in the medical device sector by supporting domestic manufacturing.
        • Leveraging our relationship with channel and   ✔Priority listing in the e-Katalog is given for products with a min. domestic
          healthcare professional
                                                          content of 40%, based on TKDN and BMP, fully implemented starting April 2022.

PRIVATE & CONFIDENTIAL                                                                                                                    10
Page 11
Medical Device Manufacturing Update
 Product Portfolio – New Product Launch                    Growing Sales and Hospital Coverage
  6 Brands, 13 SKU                Launched 1H 2025                 Coverage
                                                                     +49%            TOP HOSPITALS
                                                                                     • RS Siloam
                                                                     Sales           • RS Hermina
                                                                     +39%
                                                                                     • RS Cipto M.
                                                                                     • RS Fatmawati
                                  DECACARE    DECAMED IV                             • RS Harapan Kita




 Increasing Production Output                              2H 2025 Focus
               Total
              Output            Production Output:         • New Product Launch: Advanced
              +145%             • Own Brand (Deca)           Wound Care (Chronic)
                                • 3rd Party OEM (start     • New Hospital Coverage
                                   2H 2024)                • Export Market: Cambodia

    1H 24              1H 25
Page 12
        Digital Main Thrust: Staying Relevant & Sustain Growth
        Innovation to improve growth, productivity and asset optimization
                                                    Distributor




                Principals                                                                        Consumer

               Digital collaboration                                  Digital customer experience;
               Growth insights                      Health Provider   Self-service Order & Payment
               Self-service                                           Information & Complaint handling



           Working Capital Optimization                               Productivity & Cost Efficiency                         Growth Enabler for Principals
           •    Improved demand forecasting and optimized             •   FF and Telesales (CSO) digitalization              •   Goapotik platform for Direct To Consumer
                supply & allocation planning                                                                                     (DTC) channel
                                                                      •   GPOS B2B as mainstream digital CX touch point
           •    Improved receivables cycle through                        for customers                                      •   GPOS for selling-in and in-store marketing
                customer-process-driven collection system                                                                        and sales activation
                                                                      •   Optimize warehouse productivity & transport cost
                                                                          management                                         •   Market-flexible OMS & campaign/discount
                                                                                                                                 management

          Technology deployment driving better shareholder values

PRIVATE & CONFIDENTIAL                                                                                                                                                        12
Page 13
  Digital B2B Update: Strong Revenue and Coverage Growth,
  with Addition of New Features
                                                                              ● Single marketplace for healthcare providers supply needs
                                   Toserba                                    ● Provide digital to-market solutions for principals (pharma/non pharma)
                                  Principals                                  ● Extensive medical channel distribution networks
                                                                              ● Provide value-added services to brand/Principal: market insight, Customer reach-out,
                                                                Value           Publication etc.
                                                                Proposition   ● Provide in-store sales activation for brands
               Principals           AAM

                                                                              1H 2025 Result
                                                                                                                   Coverage
                                                                                300.000                              +26%                                14.000
                                                                                                                                                         12.000
                                                                                250.000                                                                  10.000
                                                                                                                                                         8.000
                                                                                200.000
                                                                                                                     Sales                               6.000
                                                                                150.000                              +15%                                4.000
                                                                                                                                                         2.000
                                                                                100.000                                                                  0

   Others           Hospital        Clinics        Apotek                                           1H-24                         1H-25
                                                                                                            SALES          COVERAGE
Active: >900      Active: >700   Active: >800   Active: >9000

                                                                               Value Added Service: Collaborate with 14 Principals and 40 Brands
Page 14
Digital B2C Update: Strong Revenue Growth through
Partner Expansion
                          Enabling direct to consumer model in regulated market

                                                                                                                    Demand Creations
        Brand/Principal




                                                                                  Partner Marketplaces      Tokopedia, Blibli, Lazada, GrabMart
         Collaboration




                                                                                                                                                           End Consumer
                                 7500+ Apotek
  45+




                                                                                  Health & Insurance        Good Doctor

                                                                                                            Dexa Consumer Health, Bayer, Hyphens
                                                                                  Brand Official Store      Pharma, Djembatan Dua, Ferron, Alcon

                                                                                  Bespoke DTC journeys      Cek Segitiga (Health Screening)

                                Apotek Growth in                                      Digital
                                 Digital Channel                                     Visibility



                                                  Revenue                             # Customer                                              # Transaction




 1H 2025                                                  +40%                                    +30%                                              +19%
  Result

                                                1H 2024      1H 2025              1H 2024                1H 2025                     1H 2024            1H 2025
Page 15
Delivering a Better Healthcare:
Commitment to ESG
1H 2025 Update
                                                                                                External Recognition

        Environmental                   Social                      Governance
EV Implementation
                                                             Reinforcing ethical standards
                             •   7.324 people impacted.      and professionalism by
                             •   144 community-focused       disseminating the Code of
                                 activities.                 Ethics to all employees.
                             •   14 cities. 8 provinces. 3
                                 islands.                    July 2nd, 2025
                                                                                             IDX Channel Anugerah ESG Award
Community Waste Management                                                                   2025 in the main category for the
Waste Facility Donation &                                                                    healthcare sector.
Clean-Up Environment Event
                                                                                             The award was received by the
                                                                                             Human Resources & Sustainability
                                                                                             Director during a ceremony at the
                                                                                             Main Hall of the Indonesia Stock
                                                                                             Exchange on Friday, July 4, 2025.
Page 16
         Company Strategy – Plan for 2026
            1       Continue Driving Market Growth
                         •   New Principal Exploration: Existing & New Segments
                         •   Strengthen coverage: OOP & BPJS Market, including new channel exploration
                         •   Exploring prudently for presence in some countries within ASEAN
                         •   Continue exporting “Stardec” own product to countries within ASEAN Region

            2       Strengthening and Modernizing Distribution System
                         • Capacity Expansion: Cold Chain & Non Cold Chain
                         • AI implementation in Business Process: Growth Exploration, Improve Productivity & Accuracy
                         • Exploration of Automatic System in Warehouse Infrastructure

            3       Expanding Medical Device Portfolio
                         • Strengthen Own Product “Stardec” Portfolio: New Products Launch
                         • Expanding “Agency” Product Portfolio: Orthopedics & Phlebology, Minimally Invasive Surgery, and Anatomic
                           Pathology

            4       Commitment to ESG
                         • Climate and Energy: Lower Emission & Renewable Energy
                         • Continue the Community Engagement & Contribution thru Argon Peduli

PRIVATE & CONFIDENTIAL                                                                                                                16
Page 17
             Medela Potentia:
             A Sustainable
             Healthcare Business

             Thank You

             www.medela-potentia.com
             investor.relations@medela-potentia.com
PRIVATE & CONFIDENTIAL

File

File Open PDF
Source IDX
Size2.43 MB
Published4 Sep 2025
Pages17
Characters37,850
Text sourceEmbedded text layer
OCR confidence—

Names mentioned 7 people and organisations named in the text · linked when the evidence is strong

linked org Medela Potentia p.3 ×7
possible org PT Ekon Prima p.2
possible person Dra. Hetty Soetikno p.2
unresolved org Minister of Health p.3
unresolved org PT Anugrah Argon p.7
unresolved org PT Deca Metric p.7
unresolved org Indonesia Stock Exchange p.15

Extraction attempts how the parser did, and what it refused

Nothing structured was extracted from this document — the attempts below say why.

No extraction attempted yet.

Other files in this announcement 1

↑↓ select ↵ open ⇧↵ see every result